DK1056856T3 - Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf - Google Patents
Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse derafInfo
- Publication number
- DK1056856T3 DK1056856T3 DK99911020T DK99911020T DK1056856T3 DK 1056856 T3 DK1056856 T3 DK 1056856T3 DK 99911020 T DK99911020 T DK 99911020T DK 99911020 T DK99911020 T DK 99911020T DK 1056856 T3 DK1056856 T3 DK 1056856T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- neurotrophic factor
- formation
- ciliary neurotrophic
- modified ciliary
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/031,693 US6472178B1 (en) | 1998-02-27 | 1998-02-27 | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
PCT/US1999/004430 WO1999043813A1 (en) | 1998-02-27 | 1999-02-26 | Modified ciliary neurotrophic factor, method of making and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1056856T3 true DK1056856T3 (da) | 2002-05-06 |
Family
ID=21860892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99911020T DK1056856T3 (da) | 1998-02-27 | 1999-02-26 | Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf |
Country Status (14)
Country | Link |
---|---|
US (4) | US6472178B1 (da) |
EP (1) | EP1056856B1 (da) |
JP (1) | JP4330796B2 (da) |
AT (1) | ATE212375T1 (da) |
AU (1) | AU749660B2 (da) |
CA (1) | CA2320402C (da) |
DE (1) | DE69900816T2 (da) |
DK (1) | DK1056856T3 (da) |
ES (1) | ES2168006T3 (da) |
HK (1) | HK1033336A1 (da) |
IL (2) | IL137858A0 (da) |
NZ (1) | NZ506267A (da) |
PT (1) | PT1056856E (da) |
WO (1) | WO1999043813A1 (da) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
HUP0203057A3 (en) * | 1999-08-13 | 2005-07-28 | Regeneron Pharma | Modified ciliary neurotrophic factor, method of making and methods of use thereof |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
CZ20032080A3 (cs) * | 2001-02-01 | 2003-10-15 | Biogen, Inc. | Varianty neublastinu, fúzní polypeptid obsahující variantu neublastinu a farmaceutická kompozice obsahující neublastin pro léčení poruch nervového systému |
EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050064555A1 (en) * | 2003-07-09 | 2005-03-24 | Xencor, Inc. | Ciliary neurotrophic factor variants |
EP1669350B1 (en) | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
WO2006017156A2 (en) * | 2004-07-09 | 2006-02-16 | Regeneron Pharmaceuticals, Inc. | Methods for identifying a candidate for treatment of obesity |
AU2005272627A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
EP1784203B1 (en) | 2004-08-19 | 2010-06-30 | Biogen Idec MA Inc. | Refolding transforming growth factor beta family proteins |
EP1814590B2 (en) | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
GB0425625D0 (en) * | 2004-11-22 | 2004-12-22 | Royal College Of Surgeons Ie | Treatment of disease |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
RU2008116844A (ru) | 2005-09-29 | 2009-11-10 | Мерк энд Ко., Инк. (US) | Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4 |
CA2625416A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
AU2006312557B2 (en) | 2005-11-10 | 2011-12-08 | Msd K.K. | Aza-substituted spiro derivative |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
US8796215B2 (en) * | 2007-03-16 | 2014-08-05 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
EP2009103A1 (en) * | 2007-03-16 | 2008-12-31 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neurotrophic peptides |
US8592374B2 (en) * | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
US8796214B2 (en) * | 2007-03-16 | 2014-08-05 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
EP2142205B1 (en) | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
EP2272841A1 (en) | 2008-03-28 | 2011-01-12 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
CA2731358A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014274812B2 (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE903130A1 (en) | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
EP0446931A1 (en) | 1990-03-14 | 1991-09-18 | FIDIA S.p.A. | Human ciliary neuronotrophic factor, DNA sequence encoding the factor, and production of the factor by recombinant technology |
IL98304A (en) | 1990-06-01 | 2008-08-07 | Regeneron Pharma | The ciliary neurotrophic factor receptor |
AU2925392A (en) * | 1991-11-11 | 1993-06-15 | Fidia S.P.A. | Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor |
ATE404683T1 (de) * | 1992-09-25 | 2008-08-15 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
WO1997012635A1 (en) * | 1995-10-02 | 1997-04-10 | Cytotherapeutics, Inc. | Method for treating amyotrophic lateral sclerosis |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US6391312B1 (en) | 1997-01-23 | 2002-05-21 | Sumitomo Pharmaceuticals Co., Limited | Remedies for diabetes |
-
1998
- 1998-02-27 US US09/031,693 patent/US6472178B1/en not_active Expired - Lifetime
-
1999
- 1999-02-26 DK DK99911020T patent/DK1056856T3/da active
- 1999-02-26 JP JP2000533553A patent/JP4330796B2/ja not_active Expired - Lifetime
- 1999-02-26 EP EP99911020A patent/EP1056856B1/en not_active Expired - Lifetime
- 1999-02-26 IL IL13785899A patent/IL137858A0/xx active IP Right Grant
- 1999-02-26 AU AU29763/99A patent/AU749660B2/en not_active Expired
- 1999-02-26 DE DE69900816T patent/DE69900816T2/de not_active Expired - Lifetime
- 1999-02-26 CA CA2320402A patent/CA2320402C/en not_active Expired - Lifetime
- 1999-02-26 PT PT99911020T patent/PT1056856E/pt unknown
- 1999-02-26 AT AT99911020T patent/ATE212375T1/de active
- 1999-02-26 NZ NZ506267A patent/NZ506267A/xx not_active IP Right Cessation
- 1999-02-26 ES ES99911020T patent/ES2168006T3/es not_active Expired - Lifetime
- 1999-02-26 WO PCT/US1999/004430 patent/WO1999043813A1/en active IP Right Grant
-
2000
- 2000-05-24 US US09/577,468 patent/US6767894B1/en not_active Expired - Lifetime
- 2000-08-14 IL IL137858A patent/IL137858A/en not_active IP Right Cessation
-
2001
- 2001-01-25 US US09/770,361 patent/US20020123462A1/en not_active Abandoned
- 2001-05-19 HK HK01103460A patent/HK1033336A1/xx not_active IP Right Cessation
-
2002
- 2002-10-28 US US10/281,643 patent/US7119066B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2976399A (en) | 1999-09-15 |
WO1999043813A1 (en) | 1999-09-02 |
EP1056856A1 (en) | 2000-12-06 |
IL137858A0 (en) | 2001-10-31 |
US20030144199A1 (en) | 2003-07-31 |
PT1056856E (pt) | 2002-07-31 |
CA2320402A1 (en) | 1999-09-02 |
NZ506267A (en) | 2003-04-29 |
US20020123462A1 (en) | 2002-09-05 |
DE69900816T2 (de) | 2002-08-29 |
US6472178B1 (en) | 2002-10-29 |
ES2168006T3 (es) | 2002-05-16 |
IL137858A (en) | 2008-04-13 |
CA2320402C (en) | 2010-10-12 |
AU749660B2 (en) | 2002-07-04 |
HK1033336A1 (en) | 2001-08-24 |
US6767894B1 (en) | 2004-07-27 |
EP1056856B1 (en) | 2002-01-23 |
ATE212375T1 (de) | 2002-02-15 |
JP2002504370A (ja) | 2002-02-12 |
DE69900816D1 (de) | 2002-03-14 |
JP4330796B2 (ja) | 2009-09-16 |
US7119066B2 (en) | 2006-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1056856T3 (da) | Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf | |
DE69534130D1 (de) | Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen. | |
DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
BG102999A (en) | New 2,3-diasubstituted-4-(3h)-quinazolinons | |
EP1129089A4 (en) | SPIRO-INDOLINS AS Y5 RECEPTOR ANTAGONISTS | |
BG105082A (en) | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists | |
EE04221B1 (et) | Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel | |
DE68900371D1 (de) | Textile struktur zur herstellung von schichtstoffen und schichtformteile, die diese struktur enthalten. | |
CA2001572A1 (en) | Compositions for treating tobacco withdrawal symptoms | |
ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
CA2212563A1 (en) | Process for obtaining medically active fractions from sea cucumbers | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
DE3886382T2 (de) | Wärmestabiles cyclodextrin glycosyl-transferase, deren herstellung und verwendung. | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
NO894532L (no) | Titandioksyd, fremgangsmaate for dets fremstilling og anvendelse derav. | |
NO20000731D0 (no) | Neisseria-lactodweeinbindingsprotein | |
FR2662058B1 (fr) | Bijou dont l'element decoratif, pierre fine ou autres elements decoratifs, peut etre monte amovible sur son support. | |
IL154419A0 (en) | The treatment of inflammatory disorders | |
NZ514691A (en) | Method to type prion proteins | |
HUP0203057A2 (hu) | Módosított ciliáris nerotróf faktor, ennek előállítási és használati módszere | |
WO2001089550A3 (en) | Use of ciliary neurotrophic factor | |
DE3870912D1 (de) | 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon. | |
EP1032266A4 (en) | USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS |